Edwin Alberty WARDHANA, Edwin SRIDANA, Putu Gede BUDIANA

Managing mechanical mitral valve on warfarin therapy with gross hematuria: A case report with unfractionated heparin as a bridging therapy

A dilemma can happen to a physician when managing bleeding case on a patient with mechanical heart valve with anticoagulant therapy. Major bleeding on anticoagulant treatment usually affects gastrointestinal tract (40-60 %) and urinary tract (15%). To manage the bleeding, vitamin K was restrictedly used in a patient with a mechanical heart valve and only can be used if there is major bleeding. The hypercoagulable state also must be considered when reinitiating warfarin therapy, once the bleeding already stopped. A 51-year-old female with St Jude Medical mechanical mitral valve replacement for 13 years and on regular warfarin therapy came with gross hematuria. INR l evel was 5.6, and nothing was found that can be the cause of the bleeding from the urinalysis, Urology ultrasonography, and CT scan. Warfarin was stopped for 3 days, and bleeding still occurred. Unfractionated heparin then was given to the patient to prevent thromboembolism event and as a bridging therapy. On the sixth day, hematuria was stopped, and hemoglobin was reduced only by 2 mg/dL. No rebleeding was found from the patient until 3 months later.

PDF

___

1. Prashanth Panduranga, Mohammed Al-Mukhaini, Muhanna Al-Muslahi, Mohammed A Haque, Abdullah Shehab. Management dilemmas in patients with mechanical heart valves and warfarin-induced major bleeding. World J Cardiol 2012; 4: 54-59.

2. Radaelli F, Dentali F, Repici A, et al. Management of anticoagulation in patients with acute gastrointestinal bleeding. Dig Liver Dis 2015; 47: 621-627.

3. Opie LH and Gersh BJ. 2013. Drugs For The Heart. Elsevier Saunders: Philadelphia.

4. Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 129: 2440-2492.

5. Baumgartner H, Falk V, Bax JJ, 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 2017; 38: 2739- 2791.

6. Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3: 692-694.

7. Ekim H, Akbayrak H, Başel H, et al. Management of prosthetic mitral valve thrombosis. Eastern Journal of Medicine. 2005; 10: 10-14.

8. Katzung BG and Trevor AJ. 2015. Basic & Clinical Pharmacology 13th Ed. McGraw-Hill Education: San Fransisco.

9. Charokopos N, Antonitsis P, Artemiou P, et al. Acute mechanical prosthetic valve thrombosis after initiating oral anticoagulation therapy. Is bridging anticoagulation with heparin required? Interact Cardiovasc Thorac Surg 2009; 9: 685-687.

10. Rehman HU. Paradoxical Increased Risk of Thrombosis after Initiation of Vitamin K Antagonists in Thromboembolic Disease. J Clin Case Rep 2013; 3: 121.

11. Khalid A Binymin, Magda Nasher, and Dipti Patel. Warfarin-induced deep vein thrombosis. Int Med Case Rep J 2014; 7: 123-125.